Stereotactic Radiosurgery and Cetuximab with or without Docetaxel in Treating Patients with Recurrent Head and Neck Cancer Previously Treated with Radiation Therapy
- Histologically-proven recurrent squamous cell carcinoma of the head and neck (SCCHN), who has received prior radiotherapy with or without chemotherapy; new primary is allowed if location is in a previously irradiated field; biopsy is recommended for each recurrence but is not mandated per study; this will be at the discretion of the principal investigator
- Prior radiation dose of at least 50 gray (Gy)
- Disease confined to locoregional site and can be encompassed in a stereotactic body radiosurgery “portal”
- Tumor must be deemed to be inoperable or unresectable either by clinical or radiographic criteria; these criteria include encasement of great vessels, vertebral invasion or undue peri-operative risk
- Prior surgery for recurrent or new SCCHN is allowed in previously irradiated patients; a minimum of 4 weeks should elapse between any surgery and treatment on study; however, high-risk pathologic features should be present, such as positive margins, positive lymphadenopathy, perineural or angiolymphatic invasion
- Karnofsky performance status >= 60 (Eastern Cooperative Oncology Group [ECOG] 0-1)
- Prior treatment with an endothelial growth factor receptor (EGFR) inhibitor is allowed if it was a part of prior curative therapy and was completed at least 30 days prior to commencement of study therapy
- Any number of prior chemotherapy regimens are allowed
- Measurable disease on imaging studies (magnetic resonance imaging [MRI], computed tomography [CT], PET-CT or physical exam)
- Estimated life expectancy > 12 weeks
- No prior radiation therapy or chemotherapy within 1 month of study enrollment
- Absolute neutrophil count (ANC) > 1000
- Platelet (PLT) > 75,000
- Serum creatinine < 2.5 mg/dL
- Bilirubin < 1.5 x upper limits of normal (ULN)
- Diabetes must be controlled prior to PET-CT scanning (blood glucose < 200 mg/dL)
- Ability to provide written informed consent
- Evidence of distant metastasis on upright chest x-ray (CXR), computed tomography (CT) or other staging studies
- Patients in their reproductive age group should use an effective method of birth control; patients who are breast-feeding, or have a positive pregnancy test will be excluded from the study
- Any co-morbidity or condition of sufficient severity to limit full compliance with the protocol per assessment by the investigator
- Concurrent serious infection
- History of known hypersensitivity to cetuximab, docetaxel or similar agents
I. To determine the 1-year locoregional progression-free survival (PFS) of previously irradiated patients with squamous cell carcinoma of the head and neck (SCCHN) treated with SBRT (stereotactic radiosurgery) and cetuximab and docetaxel.
II. To evaluate the acute and late toxicities associated with the above therapy.
I. To evaluate the impact of adjuvant docetaxel and cetuximab on incidence of distant disease.
II. To determine the objective response rate, PFS, and overall survival (OS) of the novel regimen.
III. To evaluate the impact of docetaxel on response rates with SBRT.
IV. To assess the toxicity of combination docetaxel-cetuximab and SBRT.
V. To evaluate changes in tumor glucose metabolism post-therapy as assessed by fludeoxyglucose F 18 (FDG)-positron emission tomography (PET).
VI. To evaluate the expression of tumor-specific biomarkers before and after treatment.
VII. To evaluate the impact of study interventions on patient-reported quality of life (PR-QOL).
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive cetuximab intravenously (IV) over 120 minutes on day -7 one week prior to stereotactic radiosurgery (SRS). Patients undergo SRS for a total of 5 fractions and receive concurrent cetuximab IV over 60 minutes and docetaxel IV over 60 minutes on days 0 and 8. Patients then receive cetuximab IV over 60 minutes and docetaxel IV over 60 minutes weekly for 12 weeks in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive cetuximab IV over 120 minutes on day -7 one week prior to SRS. Patients then undergo SRS and receive concurrent cetuximab as in Arm I. Patients then receive cetuximab IV over 60 minutes weekly for 12 weeks in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 6-8 weeks and then every 3 months for 16 months.
Trial Phase Phase II
Trial Type Treatment
David Anthony Clump
- Primary ID 11-112
- Secondary IDs NCI-2014-01954, UPCI 11-112, REN13090047
- Clinicaltrials.gov ID NCT02057107